CHF 0.84
(-6.44%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | -105.22 Million CHF | -133.4% |
2022 | -43.36 Million CHF | -5.09% |
2021 | -41.26 Million CHF | -38.15% |
2020 | -29.87 Million CHF | -38.04% |
2019 | -21.63 Million CHF | 25.93% |
2018 | -29.21 Million CHF | 25.05% |
2017 | -38.97 Million CHF | -8.36% |
2016 | -35.97 Million CHF | -12.79% |
2015 | -31.89 Million CHF | -49.36% |
2014 | -21.35 Million CHF | -35.73% |
2013 | -15.73 Million CHF | 2.23% |
2012 | -16.08 Million CHF | 28.34% |
2011 | -22.45 Million CHF | 3.63% |
2010 | -23.29 Million CHF | -142.47% |
2009 | -9.6 Million CHF | 85.54% |
2008 | -66.45 Million CHF | -12.4% |
2007 | -59.12 Million CHF | 18.49% |
2006 | -72.53 Million CHF | -106.98% |
2005 | -35.04 Million CHF | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q2 | 1.34 Million CHF | 0.0% |
2023 Q2 | -79.64 Million CHF | 0.0% |
2023 Q4 | -21.57 Million CHF | 0.0% |
2023 FY | -101.21 Million CHF | -133.4% |
2022 Q2 | -28.85 Million CHF | 0.0% |
2022 Q4 | -14.5 Million CHF | 0.0% |
2022 FY | -43.36 Million CHF | -5.09% |
2021 FY | -41.26 Million CHF | -38.15% |
2021 Q4 | -15.89 Million CHF | 0.0% |
2021 Q2 | -25.37 Million CHF | 0.0% |
2020 FY | -29.87 Million CHF | -38.04% |
2020 Q2 | -13.51 Million CHF | 0.0% |
2020 Q4 | -16.35 Million CHF | 0.0% |
2019 FY | -21.63 Million CHF | 25.93% |
2019 Q2 | -10.31 Million CHF | 0.0% |
2019 Q4 | -11.32 Million CHF | 0.0% |
2018 FY | -29.21 Million CHF | 25.05% |
2018 Q2 | -14.68 Million CHF | 0.0% |
2018 Q4 | -14.52 Million CHF | 0.0% |
2017 Q2 | -20.34 Million CHF | 0.0% |
2017 FY | -38.97 Million CHF | -8.36% |
2017 Q4 | -18.63 Million CHF | 0.0% |
2016 FY | -35.97 Million CHF | -12.79% |
2016 Q2 | -18.82 Million CHF | 0.0% |
2016 Q4 | -17.14 Million CHF | 0.0% |
2015 FY | -31.89 Million CHF | -49.36% |
2015 Q4 | -14.84 Million CHF | 0.0% |
2015 Q2 | -17.05 Million CHF | 0.0% |
2014 Q4 | -11.03 Million CHF | 0.0% |
2014 FY | -21.35 Million CHF | -35.73% |
2014 Q2 | -10.31 Million CHF | 0.0% |
2013 Q4 | -7.3 Million CHF | 0.0% |
2013 FY | -15.73 Million CHF | 2.23% |
2013 Q2 | -8.42 Million CHF | 0.0% |
2012 FY | -16.08 Million CHF | 28.34% |
2012 Q4 | -4.04 Million CHF | 2.87% |
2012 Q1 | -4.16 Million CHF | 0.0% |
2012 Q2 | -4.16 Million CHF | 0.0% |
2012 Q3 | -4.16 Million CHF | 0.0% |
2011 Q1 | -5.73 Million CHF | 0.0% |
2011 Q2 | -5.73 Million CHF | 0.0% |
2011 Q3 | -5.73 Million CHF | 0.0% |
2011 Q4 | -4.16 Million CHF | 27.38% |
2011 FY | -22.45 Million CHF | 3.63% |
2010 FY | -23.29 Million CHF | -142.47% |
2010 Q4 | -5.73 Million CHF | 1.57% |
2010 Q3 | -5.82 Million CHF | 0.0% |
2010 Q2 | -5.82 Million CHF | 0.0% |
2010 Q1 | -5.82 Million CHF | 0.0% |
2009 Q2 | -2.4 Million CHF | 0.0% |
2009 Q4 | -5.82 Million CHF | -142.47% |
2009 Q3 | -2.4 Million CHF | 0.0% |
2009 FY | -9.6 Million CHF | 85.54% |
2009 Q1 | -2.4 Million CHF | 0.0% |
2008 Q1 | -16.61 Million CHF | 0.0% |
2008 Q4 | -2.4 Million CHF | 85.54% |
2008 Q3 | -16.61 Million CHF | 0.0% |
2008 FY | -66.45 Million CHF | -12.4% |
2008 Q2 | -16.61 Million CHF | 0.0% |
2007 Q3 | -14.78 Million CHF | 0.0% |
2007 Q1 | -14.78 Million CHF | 0.0% |
2007 Q4 | -16.61 Million CHF | -12.4% |
2007 FY | -59.12 Million CHF | 18.49% |
2007 Q2 | -14.78 Million CHF | 0.0% |
2006 Q3 | -18.13 Million CHF | 0.0% |
2006 Q2 | -18.13 Million CHF | 0.0% |
2006 Q1 | -18.13 Million CHF | 0.0% |
2006 FY | -72.53 Million CHF | -106.98% |
2006 Q4 | -14.78 Million CHF | 18.49% |
2005 FY | -35.04 Million CHF | 0.0% |
2005 Q4 | -18.13 Million CHF | -106.93% |
2005 Q3 | -8.76 Million CHF | 0.0% |
2005 Q2 | -8.76 Million CHF | 0.0% |
2005 Q1 | -8.76 Million CHF | 0.0% |
2004 Q4 | -8.76 Million CHF | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Addex Therapeutics Ltd | -10.55 Million CHF | -896.847% |
BB Biotech AG | -206.6 Million CHF | 49.068% |
Basilea Pharmaceutica AG | 10.45 Million CHF | 1106.884% |
Idorsia Ltd | -297.92 Million CHF | 64.679% |
Kuros Biosciences AG | -13.72 Million CHF | -666.587% |
Molecular Partners AG | -61.98 Million CHF | -69.769% |
Relief Therapeutics Holding AG | -98.18 Million CHF | -7.179% |
Santhera Pharmaceuticals Holding AG | 54.78 Million CHF | 292.088% |